Answers are grounded in this paper and cite their sources.
Analysis strengthens connection between chronic kidney disease and cardiometabolic risks through eGFR correction in relevant populations, suggesting the need for reevaluation of risk assessments.
Serum creatinine (SCr)-based estimated glomerular filtration rate (eGFR) is the most widely applied marker of kidney function in clinical and epidemiological settings. However, its validity is limited, among other factors, by the dependence of serum creatinine levels on muscle mass. Higher lean mass leads to elevated serum creatinine levels independent of kidney function, potentially introducing systematic bias in eGFR estimation. While chronic kidney disease is a recognized and impactful cardiometabolic risk factor, confounding effects may weaken the associations of eGFRSCr with adverse metabolic and cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Helk et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: